Board of Directors


Non-Executive Members


Peter B. Corr

Dr. Corr, a pharmaceutical industry veteran of more than 26 years, will help guide the company as it completes a private financing underway and advances its clinical programs using antimicrobial Bisphosphocins for the treatment of serious infections of the lungs, bladder, skin and other tissues, including those caused by antibiotic-resistant bacteria, yeast and fungi.


Dr. Corr, who until December 2006, served as Senior Vice President for Science and Technology of Pfizer Inc., and also headed up worldwide pharmaceutical research and development for Pfizer, previously served as Executive Vice President, Pfizer Global Research & Development and President, Worldwide Development.  He also served as Senior Vice President, Discovery Research, at Monsanto/Searle and then, President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis.


Dr. Corr is Co-Founder and Managing General Partner of Auven Therapeutics Management LLLP., and was Chairman of the Board of Directors for ADC Therapeutics, S.A., founded by Auven, from its inception in 2011 through the completion of its upsized $267 million initial public offering in May, 2020.  Dr. Corr is Founder and Chairman of the Board of Imvax Inc., a research and development company focused on cancer with an initial emphasis on glioblastoma and other solid tumors.


In addition, Dr. Corr has served as Chairman of the Science & Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA); Chairman of the PhRMA Foundation Board of Directors; and Chairman of the Hever Group for six years, representing Chief Scientific Officers (CSO’s) across the European and U.S. based pharmaceutical industry.  He is a former Governor of the New York Academy of Sciences (and previous Chairman of the Board of Governors).  Additionally, he was Chairman of the Board of the International Partnership for Microbiocides and Chairman of the Board of Directors for the Critical Path Institute.  He served as a founding member of the Board of Directors of Furiex Pharmaceuticals, Inc., until the sale of the company in 2014.  He is a Founder and Chairman Emeritus of the Board of Patient Assist VI which provides medicines to indigent patients in the U.S. Virgin Islands.  He currently serves on the National Council for Washington University School of Medicine.


Dr. Corr received his doctorate from Georgetown University School of Medicine and spent 18 years as a researcher in molecular biology and pharmacology at Washington University, St. Louis, ultimately becoming Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology.  His research has been published in more than 160 scientific manuscripts.  Dr. Corr is the recipient of numerous awards and honors.

Geoffrey F. Cox, Ph.D.

Dr. Cox is an independent consultant to the Biotechnology and Life Sciences Industry and Principal of Beacon Street Advisors LLC. Dr. Cox has extensive experience in the biotechnology industry in a number of positions as a Senior Executive and Chief Executive Officer and also as a Board Director, and Chairman, of both public and private companies. He is a director and cofounder of Actu8 Vaccine Technologies Ltd., a development stage company focused on Immune oncology. Dr. Cox serves on the Board of Vaxart Inc., a public company.


From 2011 to 2013, Dr. Cox was a Partner with Red Sky Partners LLC. From 2001 to 2010, he was Chairman, President and Chief Executive Officer of GTC Biotherapeutics Inc. and from 1997 to 2001 Chairman, President and Chief Executive Officer of Aronex Pharmaceuticals Inc., both biotechnology companies. From 1984 to 1997, he was employed by Genzyme Corporation Inc., last serving as its Executive Vice President, Operations. Prior to that, he was General Manager Operations for Gist Brocades UK.


Dr. Cox is a past Chairman of MassBio, the Massachusetts Biotechnology Council and continues as a director. He also served for a number of years on the Board of the Biotechnology Industries Association (BIO), together with the Health Governing and Emerging Companies Sections of BIO. Dr. Cox received a BSc. in biochemistry from the University of Birmingham, UK and a Ph.D. in biochemistry from the University of East Anglia, UK.

Leonard J. DeRoma

Mr. DeRoma began his career in the 1970s at Citibank’s corporate finance department in strategic planning, private placements and mergers and acquisitions. He helped pioneer one of the first strategic planning services for Citibank corporate finance clients. He then spent the next 20 years in senior positions in fixed-income trading for a number of financial institutions, including Citibank, Lehman Brothers, Barclays Capital and Keybank-McDonald Investments, managing large components of their domestic and foreign fixed-income trading, sales, derivatives, research, underwritings and foreign exchange businesses. He served as the President of Barclay’s U.S. securities business, was senior advisor to the U.S. Asset Liability Committee and chaired the U.S. Credit and Risk Management Committee.


Mr. DeRoma returned to corporate finance, forming Wildwood Capital LLC, a small boutique advisory firm focused on strategic advice, mergers and acquisitions, and fund raising for small and middle market companies. He later was a founding partner of Invictus Consulting Group, an advisory company oriented towards the strategic needs of community banks. In addition, he has served as a director of a number of public and private companies and funds. He has also served on several industry boards and associations, including the Public Securities Association and the Bond Market Association. He is a member of Monk Street Partners, LLC, an intellectual property commercialization company and senior advisor to ProActive Health Services and to Trusted Networks, Inc. He has been a speaker at numerous conferences on credit, liquidity and markets in the U.S., Europe and Asia. Mr. DeRoma has a B.S. in Electrical Engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.

Charlie Wright

Charles F. Wright

Mr. Wright has had a long and successful career as a businessman and investor. He is the Chairman of The Fall River Group, Inc. a manufacturing organization of foundries located in Wisconsin, He has been associated with Fall River for over 45 years. He serves on the board of Prolitec Inc. and on the advisory board of Total Multimedia, Incorporated. Mr. Wright is a partner and Chairman of Quaestus & Co. Inc. which is a venture capital and private equity firm. He received a BA in Speech from the University of South Florida and an MBA from the Harvard Business School.


Executive Member

Steve Parkinson
Executive Director, Chief Executive Officer and President

Mr. Parkinson has more than 30 years of experience in the biopharmaceutical industry. As co-founder and CEO of TranXenoGen, Mr. Parkinson oversaw its IPO and admission to AIM in July of 2000, increasing its market value from $90M to $250M within one year. As President and CEO of CereMedix, a drug discovery and development company, he advanced their first product to clinical trials. Mr. Parkinson has raised both public and private capital, built management teams, managed M&A, in-licensed and out-licensed products/technology, and secured major industry contracts and collaborations for a number of companies including Advanced Cell Technology where he was CEO, Johnson & Johnson, PPL Therapeutics, Genzyme Transgenics and Fermetech Ltd.